Citrate Anticoagulation for Postdilution Hemofiltration
NCT ID: NCT03969966
Last Updated: 2020-05-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
100 participants
OBSERVATIONAL
2019-01-14
2021-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study Using Citrate to Replace Heparin in Babies Requiring Extracorporeal Membrane Oxygenation (ECMO)
NCT00968565
The Effect of Citrate Dialysate on Clot Formation and Anemia in Hemodialysis Patients
NCT03470727
The Effectiveness and Safety of 4% Sodium Citrate as a Lock Solution in Central Venous Hemodialysis Catheter
NCT05188339
Citrate Pharmacokinetics and Regional Citrate Anticoagulation in CRRT
NCT00948558
Citrate Pharmacokinetics in Critically Ill Liver Failure Patients Receiving CRRT
NCT04959110
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
We here study prospectively patients with AKI who are treated with continuous veno-venous haemofiltration using an RCA protocol.
We will evaluate all parameters of CRRT including filter running times, delivered dialysis dose, causes for treatment interruption and control of pH and electrolytes.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
renal replacement therapy as clinically indicated
Continuous renal replacement therapy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* critical illness and treatment at ICU
Exclusion Criteria
* pregnancy or breast feeding
* severe lactate acidosis ( \> 10 mmol/l) for longer than 6 hours and pH \< 7.2
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Diamed GmbH, Cologne, Germany
UNKNOWN
Heinrich-Heine University, Duesseldorf
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Klinik für Anästhesiologie
Prof. Dr. D. Kindgen-Milles
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Intensivstation ZOM1 Klinik für Anästhesiologie Universitätsklinikum Düsseldorf
Düsseldorf, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Dimski T, Brandenburger T, Vollmer C, Kindgen-Milles D. A safe and effective protocol for postdilution hemofiltration with regional citrate anticoagulation. BMC Nephrol. 2024 Jul 9;25(1):218. doi: 10.1186/s12882-024-03659-y.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2018-82
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.